Response to infliximab in Crohn's disease: Genetic analysis supporting expression profile

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Medrano, Luz María ^a   Taxonera, Carlos ^a   González Artacho, Cristina ^b   Pascual, Virginia ^a   Gómez García, María ^b   Barreiro De Acosta, Manuel ^c   Pérez Calle, José L ^d   Bermejo, Fernando ^e   López Sanromán, Antonio ^f   Martín Arranz, Dolores ^g   Gisbert, Javier P ^h,i   Mendoza, Juan Luis ^a   Martín, Javier ^j   Núñez, Concepción ^a   Urcelay, Elena ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c University Hospital of Santiago de Compostela   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; INFLIXIMAB; INTERLEUKIN 11; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 6; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CELL ADHESION MOLECULE; CELL CYCLE PROTEIN; G0S2 PROTEIN, HUMAN; TNFAIP6 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; G0S2 GENE; GENE; GENE EXPRESSION PROFILING; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ADOLESCENT; GENETICS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; CALGRANULIN A; CALGRANULIN B; CELL ADHESION MOLECULES; CELL CYCLE PROTEINS; CROHN DISEASE; FEMALE; GENOTYPE; HUMANS; INFLIXIMAB; INTERLEUKIN-11; MALE; YOUNG ADULT;

EID: 84939631213     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/318207     Document Type: Article

References (27)

1. C. Abraham and J. H. Cho, Inflammatory bowel disease, The New England Journal of Medicine, vol. 361, no. 21, pp. 2066-2078, 2009.
2. A. Franke, D. P. McGovern, J. C. Barrett et al., Genome-wide meta-analysis increases to 71 the number of confirmed Crohns disease susceptibility loci, Nature Genetics, vol. 42, no. 12, pp. 1118-1125, 2010.
3. P. Rutgeerts, B. G. Feagan, G. R. Lichtenstein, et al., Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease, Gastroenterology, vol. 126, no. 2, pp. 402-413, 2004.
4. B. E. Sands, F. H. Anderson, C. N. Bernstein et al., Infliximab maintenance therapy for fistulizing Crohns disease, The New England Journal of Medicine, vol. 350, no. 9, pp. 876-885, 2004.
5. B. G. Feagan, M. Ĺemann, R. Befrits et al., Recommendations for the treatment of Crohns disease with tumor necrosis factor antagonists: an expert consensus report, Inflammatory Bowel Diseases, vol. 18, no. 1, pp. 152-160, 2012.
6. M. Cottone and V. Criscuoli, Infliximab to treat Crohns disease: an update, Clinical and Experimental Gastroenterology, vol. 4, no. 1, pp. 227-238, 2011.
7. I. Arijs, R. Quintens, L. V. Lommel et al., Predictive value of epithelial gene expression profiles for response to infliximab in Crohns disease, Inflammatory Bowel Diseases, vol. 16, no. 12, pp. 2090-2098, 2010.
8. E. J. M. Toonen, C. Gilissen, B. Franke et al., Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis, PLoS ONE, vol. 7, no. 3, Article ID e33199, 2012.
9. J. E. Lennard-Jones, Classification of inflammatory bowel disease, Scandinavian Journal of Gastroenterology, Supplement, vol. 24, no. 170, pp. 2-6, 1989.
10. M. S. Silverberg, J. Satsangi, T. Ahmad et al., Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005MontrealWorld Congress of Gastroenterology, Canadian Journal of Gastroenterology, vol. 19, supplement, pp. 5A-36A, 2005.
11. R. F. Harvey and J. M. Bradshaw, A simple index of Crohnsdisease activity, The Lancet, vol. 1, no. 8167, p. 514, 1980.
12. J. F. Colombel, W. J. Sandborn, W. Reinisch et al., Infliximab, azathioprine, or combination therapy for Crohns disease, The New England Journal ofMedicine, vol. 362, no. 15, pp. 1383-1395, 2010.
13. Y. Gonzalez-Lama, A. Lopez-San Roman, I. Marin-Jimenez et al., Open-label infliximab therapy in Crohns disease: a longterm multicenter study of efficacy, safety and predictors of response, Gastroenterology and Hepatology, vol. 31, no. 7, pp. 421-426, 2008.
14. P. Miheller, P. L. Lakatos, G. Horvath et al., Efficacy and safety of infliximab induction therapy in Crohns Disease in Central Europe-a Hungarian nationwide observational study, BMC Gastroenterology, vol. 9, article 66, 2009.
15. I. Arijs, K. Li, G. Toedter et al., Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis, Gut, vol. 58, no. 12, pp. 1612-1619, 2009.
16. K. Eggers, K. Sikora, M. Lorenz et al., RAGE-dependent regulation of calcium-binding proteins S100A8 and S100A9 in human THP-1, Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 6, pp. 353-357, 2011.
17. K. Luley, F. Noack, H. Lehnert, and N. Homann, Local calprotectin production in colorectal cancer and polyps-active neutrophil recruitment in carcinogenesis, International Journal of Colorectal Disease, vol. 26, no. 5, pp. 603-607, 2011.
18. A. C. Manolakis, A. N. Kapsoritakis, E. K. Tiaka, and S. P. Potamianos, Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease, Digestive Diseases and Sciences, vol. 56, no. 6, pp. 1601-1611, 2011.
19. H. B. Hammer, M. K. Fagerhol, T. N. Wien, andT. K. Kvien, The soluble biomarker calprotectin (a S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab, Arthritis Research and Therapy, vol. 13, no. 5, article R178, 2011.
20. C. Lood, M. Stenstrom, H. Tyden et al., Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus, Arthritis Research andTherapy, vol. 13, no. 2, article R60, 2011.
21. E. Louis, J.-Y. Mary, G. Verniermassouille et al., Maintenance of remission among patients with Crohns disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, vol. 142, no. 1, pp. 63. e5-70. e5, 2012.
22. P. Molander, C.-G. Af Bjorkesten, H. Mustonen et al., Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF blocking agents, Inflammatory Bowel Diseases, vol. 18, no. 11, pp. 2011-2017, 2012.
23. K. R. Herrlinger, T. Witthoeft, A. Raedler et al., Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohns disease, American Journal of Gastroenterology, vol. 101, no. 4, pp. 793-797, 2006.
24. G. Nagyeri, M. Radacs, S. Ghassemi-Nejad et al., TSG-6 protein, a negative regulator of inflammatory arthritis, forms a ternary complex with murine mast cell tryptases and heparin, The Journal of Biological Chemistry, vol. 286, no. 26, pp. 23559-23569, 2011.
25. H. Offenberg, N. Brunner, F. Mansilla, F. Orntoft Torben, and K. Birkenkamp-Demtroder, TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles, Molecular Oncology, vol. 2, no. 3, pp. 233-240, 2008.
26. D. Koczan, R. Guthke, H.-J. Thiesen et al., Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatorymolecules, European Journal of Dermatology, vol. 15, no. 4, pp. 251-257, 2005.
27. N. Nakamura, Y. Shimaoka, T. Tougan et al., Isolation and expression profiling of genes upregulated in bone marrowderived mononuclear cells of rheumatoid arthritis patients, DNA Research, vol. 13, no. 4, pp. 169-183, 2006.